{"id":403,"date":"2022-06-28T04:24:56","date_gmt":"2022-06-27T20:24:56","guid":{"rendered":"https:\/\/www.junshipharma.com\/join-us\/"},"modified":"2026-04-09T18:25:50","modified_gmt":"2026-04-09T10:25:50","slug":"join-us","status":"publish","type":"page","link":"https:\/\/www.junshipharma.com\/en\/join-us\/","title":{"rendered":"Careers"},"content":{"rendered":"\n
Founded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. With strong R&D capacity, Junshi Biosciences is at the cutting-edge of medical innovation. Our mission is to” Provide patients with world-class, trustworthy, affordable, and innovative drugs”<\/strong>.<\/p>\n\n\n\n We have established a globally integrated R&D process. With R&D centers in China and the US,<\/strong> we have the outstanding ability to discover and develop innovative biologics. Our strategic goal is “In China, For Global”<\/strong>.<\/p>\n<\/div>\n\n\n\n With our outstanding capacity for innovative drug discovery, strong biotechnology R&D capability, and large-scale production capacity, we have successfully developed a drug candidate portfolio with global competitiveness and a well-structured research pipeline, which covers therapeutic areas including cancer, autoimmune, metabolic, and infectious diseases. Our innovative field spans cutting-edge therapeutic modalities, including mAbs, small molecule drugs, ADCs, bsAb\/msAb, fusion protein, nucleic acid drugs and vaccines. Five of the company\u2019s products have received marketing authorizations in China and international markets, one of which is toripalimab, China\u2019s domestically developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in over 40 countries and regions including China, the US, and Europe. During the COVID-19 pandemic, Junshi Biosciences actively shouldered the social responsibilities of a Chinese pharmaceutical company through its involvement in developing etesevimab, MINDEWEI, and other novel therapies for the prevention and treatment of COVID-19.<\/p>\n\n\n\n We have two production bases in China with a combined fermentation capacity of 46,500L, undertaking the manufacturing of both investigational and commercial products.<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":" Company Introduction Founded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. With strong R&D capacity, Junshi Biosciences is at the cutting-edge of medical innovation. Our mission is to” Provide patients with world-class, trustworthy, affordable, and innovative drugs”. We have established a globally integrated […]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"templates\/join.php","meta":{"footnotes":""},"class_list":["post-403","page","type-page","status-publish","hentry"],"yoast_head":"\n
<\/figure>\n<\/div>\n<\/div>\n\n\n\n
<\/figure>\n<\/div>\n\n\n\n